Ten years of sensitivity monitoring in Europe (1994-2005)

Cefquinome gained market authorisation for the treatment of bovine pneumonia in 1994. Merck Animal Health simultaneously implemented a surveillance program to monitor the susceptibility of relevant bacteria against cefquinome.


650 P.multocida and 492 M.haemolytica were isolated from bovine respiratory disease in Europe from 1994 to 2005.

Minimum inhibitory concentrations were determined and minimum bactericidal concentrations (MBC) were determined for the pathogens isolated during 2000-2005. MIC50 and MIC90 were determined annually for each strain.


Results of the activity of cefquinome against P. multocida and M. haemolytica
Pathogen MIC50 MIC90
 P. multocida  ≤0.032 µg/ml (1994-2004)  ≤ 0.063 µg/ml (1994)
 ≤ 0.25 µg/ml (1995)
 ≤0.032 µg/ml (1994-2004)
 M. haemolytica  ≤0.032 µg/ml (1994-2004)  0.063 µg/ml (1995-1996)


Results demonstrate that cefquinome shows an unchanged high activity against the main respiratory pathogens P.multocida and M.haemolytica isolated during the last ten years in Europe. Bactericidal activity against both bacteria was shown at very low concentrations.

beef calf

Cefquinome shows consistently high activity against the main respiratory pathogens, P.multocida and M.haemolytica